AEGON ASSET MANAGEMENT UK Plc Increases Stock Holdings in Eli Lilly and Company $LLY

Key Points

• AEGON ASSET MANAGEMENT UK Plc increased its stake in Eli Lilly by 35.1% to 67,329 shares (worth $72.39 million), making LLY the fund’s 24th-largest holding and 0.9% of its portfolio.
• Eli Lilly posted strong quarterly results with revenue of $19.29 billion (+42.6% YoY) and EPS of $7.54 (beating estimates), and set FY2026 guidance of 33.5–35.0 EPS versus analysts' consensus of 33.9.
• Institutional ownership is high (82.53%), and analysts hold a consensus rating of “Moderate Buy” with an average target of $1,216.52 amid positive pipeline/M&A news, though GLP‑1 competition and early launch uptake pose short-term risks.

AEGON ASSET MANAGEMENT UK Plc raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 35.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 67,329 shares of the company's stock after purchasing an additional 17,475 shares during the quarter. Eli Lilly and Company accounts for 0.9% of AEGON ASSET MANAGEMENT UK Plc's investment portfolio, making the stock its 24th biggest holding. AEGON ASSET MANAGEMENT UK Plc's holdings in Eli Lilly and Company were worth $72,391,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Miller Global Investments LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $33,000. Dorato Capital Management purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $36,000. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after buying an additional 16 shares in the last quarter. Finally, 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after buying an additional 10 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on LLY shares. Berenberg Bank lifted their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a research note on Thursday, February 19th. Zacks Research downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 30th. Barclays started coverage on Eli Lilly and Company in a research report on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 target price on the stock. Truist Financial reiterated a "buy" rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Finally, Wells Fargo & Company boosted their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,216.52.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large AI gene‑editing partnership with Profluent (up to $2.25B) broadens Lilly’s digital biology and next‑generation genetic medicine pipeline, a long‑term growth and valuation positive. Read More.
• Positive Sentiment: Acquisition of Ajax Therapeutics (up to $2.3B) adds a JAK2 myelofibrosis program and deepens oncology exposure — complementary to recent M&A and supports analyst bullishness. Read More.
• Positive Sentiment: Analyst support and price‑target moves (e.g., Guggenheim raise) reflect confidence that acquisitions plus pipeline execution justify upside vs. the pullback. This can underpin buying interest if Q1 execution meets expectations. Read More.
• Neutral Sentiment: Wall Street forecasts strong Q1 revenue growth (~36–37%) and investors expect pipeline commentary; earnings results and management commentary will be the immediate catalyst for intraday moves. Read More.
• Neutral Sentiment: Options and trader models imply sizable post‑earnings volatility — the report could drive a sharp move either way, so risk around the print is elevated. Read More.
• Negative Sentiment: Early launch data show Foundayo prescriptions lagging a Novo rival and social chatter flags a slow oral GLP‑1 rollout; weaker uptake puts short‑term pressure on growth expectations for obesity franchise. Read More.
• Negative Sentiment: Canada approved cheaper generic weight‑loss drugs, highlighting accelerating competitive and pricing risks in the GLP‑1 market that could weigh on sales mix and margins over time. Read More.
• Negative Sentiment: Notable insider selling activity and some fund/portfolio churn reported recently; heavy sales can be perceived negatively by sentiment‑driven investors ahead of the quarter. Read More.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $851.65 on Thursday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock has a market cap of $804.65 billion, a price-to-earnings ratio of 37.11, a price-to-earnings-growth ratio of 1.03 and a beta of 0.51. The business has a fifty day moving average of $948.77 and a 200-day moving average of $985.31. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. During the same period in the previous year, the firm posted $5.32 earnings per share. The business's revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 33.9 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.